Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase
US-2019119281-A1 · Apr 25, 2019 · US
Compounds useful as kinase inhibitors
US12220401B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12220401-B2 |
| Application number | US-202318362249-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 31, 2023 |
| Priority date | Dec 16, 2015 |
| Publication date | Feb 11, 2025 |
| Grant date | Feb 11, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of the formula: wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition, wherein the pharmaceutical composition comprises a compound of the formula: wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof, and pharmaceutically acceptable excipients. 3. A method of treating a condition which is modulated by BTK in a patient in need thereof comprising administering to the patient a compound of the formula: wherein * indicates a chiral center, or a pharmaceutically acceptable salt thereof. 4. The method according to claim 3 wherein the condition modulated by BTK is cancer, lymphoma, leukemia, autoimmune diseases, inflammatory disorders, heteroimmune conditions, or fibrosis. 5. The method according to claim 4 wherein the condition modulated by BTK is selected from B-cell malignancy, B-cell lymphoma, diffuse large B cell lymphoma, chronic lymphocytic leukemia, non-Hodgkin lymphoma, ABC-DLBCL, mantle cell lymphoma, follicular lymphoma, hairy cell leukemia, B-cell non-Hodgkin lymphoma, Waldenstrom's macroglobulinemia, multiple myeloma, bone cancer, bone metastasis, arthritis, multiple sclerosis, osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, Sjögren's syndrome, and lupus. 6. The method according to claim 5 wherein the condition modulated by BTK is selected from arthritis, multiple sclerosis, osteoporosis, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease, and lupus.
Assignees
Inventors
Classifications
directly linked by a ring-member-to-ring-member bond · CPC title
non condensed and containing further heterocyclic rings · CPC title
Antineoplastic agents · CPC title
- C07D231/38Primary
Nitrogen atoms (nitro radicals C07D231/16) · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12220401B2 cover?
- This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immun…
- Who is the assignee on this patent?
- Loxo Oncology Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D231/38. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).